Immunogenicity of SIV gp120 and gp41 envelope proteins expressed as hybrid Ty-VLPs.

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

Immunogenicity of SIV gp120 and gp41 envelope proteins expressed as hybrid Ty-VLPs.

Symp Nonhum Primate Models AIDS. 1992 Nov 17-20;10:abstract no. 129. Unique Identifier : AIDSLINE PRIM10/93200965
Stasiak P; Stenner N; Stabler G; Kent K; Almond N; Kitchin P; Mills K; Layton G; Adams S; Kingsman A; British Bio-technology Ltd., Oxford, U.K.

Abstract: SIV infection of macaques has been developed as a model for AIDS resulting from HIV infection of humans. By analogy with HIV, it is likely that the envelope protein of SIV will play an important role in eliciting neutralising, and possibly protective, responses. It is therefore important to define epitopes within the SIV glycoproteins gp120 and gp41 that can induce neutralising antibodies when presented to the immune system as hybrid Ty virus-like particles (Ty-VLPs). We therefore decided to use this system to scan SIV gp120 and gp41 for neutralising determinants. Overlapping DNA fragments encoding SIV gp120 and gp41 were inserted into Ty-VLP vectors and the resulting fusion proteins assembled into particles. The purified hybrid Ty-VLPs have been used to immunise mice and the sera are being tested for their reactivity against both conformational and linear epitopes of gp120 and gp41. Previous studies by Kent et al have demonstrated that the V2 region of gp120 reacts with neutralising monoclonal antibodies. These antibodies also recognise hybrid Ty-VLPs carrying the V1 and V2 regions of gp120. Immunogenicity studies with these Ty-VLPs indicate that these particles elicit antibodies that recognise gp120 and gp 160 by both ELISA and Western blot analysis. Further investigations into the ability of these sera to induce neutralising antibodies are underway.

Keywords: Animal Antibodies, Viral/ANALYSIS Antibody Formation Blotting, Western Enzyme-Linked Immunosorbent Assay Epitopes/ANALYSIS/IMMUNOLOGY Gene Products, env/*IMMUNOLOGY HIV Envelope Protein gp120/*IMMUNOLOGY Mice Neutralization Tests Protein Conformation Recombinant Fusion Proteins/IMMUNOLOGY SIV/*IMMUNOLOGY Vaccines, Synthetic/*IMMUNOLOGY Viral Vaccines/*IMMUNOLOGY ABSTRACT
930630
M9361055

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .